Menu
Back to User profile » Dr Goh Yong Meng
Papers published by Dr Goh Yong Meng:
A comprehensive overview on osteoporosis and its risk factors
Pouresmaeili F, Kamalidehghan B, Kamarehei M, Goh YM
Therapeutics and Clinical Risk Management 2018, 14:2029-2049
Published Date: 6 November 2018
Four novel ARSA gene mutations with pathogenic impacts on metachromatic leukodystrophy: a bioinformatics approach to predict pathogenic mutations
Dehghan Manshadi M, Kamalidehghan B, Aryani O, Khalili E, Dadgar S, Tondar M, Ahmadipour F, Yong Meng G, Houshmand M
Therapeutics and Clinical Risk Management 2017, 13:725-731
Published Date: 16 June 2017
Identification of a new mutation in an Iranian family with hereditary multiple osteochondromas
Akbaroghli S, Balali M, Kamalidehghan B, Saber S, Aryani O, Yong Meng G, Houshmand M
Therapeutics and Clinical Risk Management 2017, 13:15-19
Published Date: 20 December 2016
Association of nuclear and mitochondrial genes with audiological examinations in Iranian patients with nonaminoglycoside antibiotics-induced hearing loss
Balali M, Kamalidehghan B, Farhadi M, Ahmadipour F, Ashkezari MD, Hemami MR, Arabzadeh H, Falah M, Meng GY, Houshmand M
Therapeutics and Clinical Risk Management 2016, 12:117-128
Published Date: 28 January 2016
Prevalence of the rs7903146C>T polymorphism in TCF7L2 gene for prediction of type 2 diabetes risk among Iranians of different ethnicities
Allahdini M, Kamalidehghan B, Akbari L, Azadfar P, Rahmani A, Ahmadipour F, Meng GY, Masserrat A, Houshmand M
Drug Design, Development and Therapy 2015, 9:5835-5841
Published Date: 28 October 2015
Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities
Bagheri A, Kamalidehghan B, Haghshenas M, Azadfar P, Akbari L, Sangtarash MH, Vejdandoust F, Ahmadipour F, Meng GY, Houshmand M
Drug Design, Development and Therapy 2015, 9:2627-2634
Published Date: 13 May 2015